SBFMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFMW
Sunshine Biopharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.24+0.02 (+9.02%)
Close on Oct 19, 2026
- Market cap
- $330.14K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$20.6582 (−98.84%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Sunshine Biopharma Inc. saw revenue fall 2.7% to $35.35M over the twelve months to Jun 30, 2026. Free cash flow was -$5.37M.
Revenue
$35.35M
-2.7% vs. a year earlier
Operating income
-$5.89M
TTM Q2 2026
Free cash flow
-$5.37M
TTM Q2 2026
EPS, diluted
-$2.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $330.14K
- P/E ratio
- –
- Price to sales
- 0.01
- Price to book
- 0.01
- Dividend yield
- –
- Free cash flow yield
- -1627.18%
Fundamentals
- Revenue
- $35.35M
- Net income
- -$5.83M
- EPS, diluted
- -$2.00
- Free cash flow
- -$5.37M
- Book value per share
- $20.17
- Diluted shares
- 1M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$35.35M-2.7% YoY
Gross profit
$10.71M-11.6% YoY
Operating income
-$5.89M
Net income
-$5.83M
EPS, diluted
-$2.00
Free cash flow
-$5.37M
Reported periodTrailing twelve months